Daniel S. Goldman sold AstraZeneca PLC (NASDAQ: AZN)
Daniel S. Goldman (D-NY), a U.S. Representative, has disclosed 1 trade in AstraZeneca PLC (AZN) since 2023, a single sale, worth an estimated $175K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Daniel S. Goldman sold $100,001 - $250,000 of AstraZeneca PLC (NASDAQ: AZN) on July 10, 2023. Since that trade, AZN is up +39.47% against the S&P 500 up +74.66%, an outperformance of -35.19%.
Data updated
Daniel S. Goldman's AZN trades vs the price
AZN is up +39.47% since Daniel S. Goldman sold on July 10, 2023, versus +74.66% for the S&P 500.
Performance since this trade
All Daniel S. Goldman AZN trades
Daniel S. Goldman & AZN trading FAQ
Is it legal for Daniel S. Goldman to trade AstraZeneca PLC (AZN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including AstraZeneca PLC (AZN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Daniel S. Goldman sell AZN?
Daniel S. Goldman disclosed a sale of $100,001 - $250,000 of AstraZeneca PLC (AZN) on July 10, 2023, according to public STOCK Act filings.
How has AZN performed since Daniel S. Goldman's trade?
Since Daniel S. Goldman sold AZN on July 10, 2023, the stock is up +39.47%, versus +74.66% for the S&P 500 over the same period, an outperformance of -35.19%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AZN trades?
Quantellect tracks every disclosed congressional trade in AstraZeneca PLC (AZN) on the AstraZeneca PLC congressional trading page, which aggregates filings across all members of Congress.
Daniel S. Goldman's AZN tradesAll congressional filings for AstraZeneca PLCDaniel S. Goldman's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.